KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

(MedPage Today) — Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) compared with docetaxel, the phase III KRYSTAL…

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116919

Author :

Publish date : 2025-08-08 20:14:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

Rapist Who Killed Visiting Nurse Gets 50 Years in Prison

A planet the size of Saturn could orbit the nearest Sun-like star

Related Posts

Cold-Water Immersion May Offer Health Benefits, and Also Presents Risks

Door Closes on Aggressive Perioperative BP Targets for Select Patients

‘My late husband’s organs transformed the lives of four people’

Which Docs Are Leaving the Workforce in Greater Numbers?

Where Are U.S. Antibiotics Originating? Aldosterone and Heart Disease Risk

Pronatalism and Public Health Are Incompatible

Cold-Water Immersion May Offer Health Benefits, and Also Presents Risks

Door Closes on Aggressive Perioperative BP Targets for Select Patients

‘My late husband’s organs transformed the lives of four people’

Which Docs Are Leaving the Workforce in Greater Numbers?

Where Are U.S. Antibiotics Originating? Aldosterone and Heart Disease Risk

Pronatalism and Public Health Are Incompatible

Poor Heart Health in Youth Linked With Later Pregnancy Risks

Report shows ‘stark’ gender gap in HIV prevention across West Midlands

Categories

Archives